Delcath Systems (NASDAQ:DCTH – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.19, RTT News reports. The company had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 1,007.65%. During the same quarter last year, the business earned ($0.86) earnings per share.
Delcath Systems Price Performance
Shares of NASDAQ:DCTH traded down $0.23 during midday trading on Thursday, reaching $4.86. The company had a trading volume of 175,898 shares, compared to its average volume of 217,690. Delcath Systems has a 1-year low of $2.25 and a 1-year high of $7.99. The company has a fifty day simple moving average of $4.34 and a two-hundred day simple moving average of $3.84. The company has a current ratio of 3.30, a quick ratio of 3.11 and a debt-to-equity ratio of 0.08.
Insider Buying and Selling at Delcath Systems
In other news, Director Gil Aharon acquired 26,882 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The stock was acquired at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the acquisition, the director now owns 1,069,710 shares in the company, valued at $3,979,321.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 21.10% of the company’s stock.
Institutional Investors Weigh In On Delcath Systems
Wall Street Analyst Weigh In
A number of research analysts have issued reports on DCTH shares. HC Wainwright boosted their price target on Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. StockNews.com raised shares of Delcath Systems to a “sell” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.50.
Get Our Latest Stock Analysis on Delcath Systems
About Delcath Systems
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Further Reading
- Five stocks we like better than Delcath Systems
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Roth IRA Calculator: Calculate Your Potential Returns
- Disney Stock Catches 3 Upgrades In a Single Week
- Which Wall Street Analysts are the Most Accurate?
- Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.